The proteasome is an abundant multi-enzyme complex that provides the main pathway for
degradation of intracellular proteins in eukaryotic cells. As such, it controls the levels of …

The ubiquitin-proteasome system is an important regulator of cell growth and apoptosis. The
potential of specific proteasome inhibitors to act as novel anti-cancer agents is currently …

Previously we reported that proteasome inhibitors were able to overcome Bcl-2-mediated
protection from apoptosis. Here we show that inhibition of the proteasome activity in Bcl-2 …

Protelytic enzymes are known to be associated with developmentally programmed cell
death during organ senescence and tracheary element differentiation. Recent evidence also …

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder resulting from the
clonal expansion of a transformed multipotent hematopoietic stem cell. CML is a biphasic …

The central role of the proteasome in controlling the expression of regulators of cell
proliferation and survival has led to interest in developing proteasome inhibitors as novel …

Purpose: Chronic myelogenous leukemia (CML) is characterized by the constitutive
activation of Bcr-Abl tyrosine kinase. Bcr-Abl-T315I is the predominant mutation that causes …

Interactions between the kinase inhibitor STI571 and pharmacological antagonists of the
mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK)/mitogen …

Ubiquitin/proteasome-dependent proteolysis plays an essential role in degrading regulatory
proteins and thereby controlling processes of cell proliferation and cell death (apoptosis) …

PD180970 is a novel pyrido [2, 3-d] pyrimidine class of ATP-competitive inhibitor of protein
tyrosine kinases. We found that PD180970 inhibited in vivo tyrosine phosphorylation of …